PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3323466-0 1987 Prevention of molecular self-association by sodium salicylate: effect on insulin and 6-carboxyfluorescein. Sodium Salicylate 44-61 insulin Homo sapiens 73-80 8024632-0 1994 Effect of sodium salicylate on insulin rectal absorption in humans. Sodium Salicylate 10-27 insulin Homo sapiens 31-38 8024632-4 1994 The investigated suppositories, thus, proved that sodium salicylate is effective in enhancing the rectal absorption of insulin in humans. Sodium Salicylate 50-67 insulin Homo sapiens 119-126 3323466-1 1987 The effect of sodium salicylate on the concentration-dependent self-association of insulin and 6-carboxyfluorescein (CF), as expressed by metachromasy, fluorescence, and changes in aqueous solubility, was learned. Sodium Salicylate 14-31 insulin Homo sapiens 83-90 3323466-6 1987 The water solubility of both molecules, CF and insulin, was considerably increased with the addition of increasing concentrations of salicylate to the solutions: at 37 degrees C, 2.5 M sodium salicylate solution increases the CF solubility 532 times from 12.2 to 6.5 mg.mL-1, and 1.5 M salicylate increases the solubility of insulin 7875 times, thus an aqueous solution containing 630 mg.mL-1 of insulin may be prepared. Sodium Salicylate 185-202 insulin Homo sapiens 47-54 3323466-6 1987 The water solubility of both molecules, CF and insulin, was considerably increased with the addition of increasing concentrations of salicylate to the solutions: at 37 degrees C, 2.5 M sodium salicylate solution increases the CF solubility 532 times from 12.2 to 6.5 mg.mL-1, and 1.5 M salicylate increases the solubility of insulin 7875 times, thus an aqueous solution containing 630 mg.mL-1 of insulin may be prepared. Sodium Salicylate 185-202 insulin Homo sapiens 325-332 3323466-6 1987 The water solubility of both molecules, CF and insulin, was considerably increased with the addition of increasing concentrations of salicylate to the solutions: at 37 degrees C, 2.5 M sodium salicylate solution increases the CF solubility 532 times from 12.2 to 6.5 mg.mL-1, and 1.5 M salicylate increases the solubility of insulin 7875 times, thus an aqueous solution containing 630 mg.mL-1 of insulin may be prepared. Sodium Salicylate 185-202 insulin Homo sapiens 325-332 3908178-6 1985 The inhibitory effect of epinephrine (15 ng/kg/min) upon glucose-induced insulin secretion was partially reversed by sodium salicylate, an inhibitor of endogenous prostaglandin synthesis, which increased but not normalized, either the acute insulin response and the glucose disappearance rates. Sodium Salicylate 117-134 insulin Homo sapiens 73-80 3318257-4 1987 The infusion of sodium salicylate caused a striking increase of the acute insulin response to intravenous glucose (from 14.5 +/- 4 microU/ml to 88 +/- 11 microU/ml, p less than 0.001) and restored to normal the reduced glucose tolerance (KG from 1.10 +/- 0.1% min-1 to 2.04 +/- 0.19% min-1). Sodium Salicylate 16-33 insulin Homo sapiens 74-81 3912157-3 1985 Sodium salicylate effected in type II-diabetics and metabolic healthy persons higher insulin levels. Sodium Salicylate 0-17 insulin Homo sapiens 85-92 3891465-2 1985 The present study was undertaken to evaluate the influence of sodium salicylate on the counterregulatory glucagon response to insulin-induced hypoglycemia in both insulin-dependent diabetic subjects (IDDM) and normal controls. Sodium Salicylate 62-79 insulin Homo sapiens 126-133 3891465-5 1985 The infusion of sodium salicylate (40 mg/min) during insulin-induced hypoglycemia (1 mU/kg-min for 60 min) in normal subjects caused a significant increase of the counterregulatory glucagon response both in terms of glucagon peak and integrated areas. Sodium Salicylate 16-33 insulin Homo sapiens 53-60 3891465-6 1985 Sodium salicylate itself significantly increased basal insulin and decreased glucose, but did not change basal glucagon. Sodium Salicylate 0-17 insulin Homo sapiens 55-62 3912157-6 1985 It is discussed if the results could be explained by a direct effect of Sodium salicylate on the cells ore on the metabolism of insulin and the gluconeogenesis. Sodium Salicylate 72-89 insulin Homo sapiens 128-135 6769309-0 1980 Improvement of defective insulin responses to glucose, arginine, and beta-adrenergic stimulation in diabetics by sodium salicylate. Sodium Salicylate 113-130 insulin Homo sapiens 25-32 6345247-3 1983 Stimulation of insulin secretion by intravenous glucose, tolbutamide or sodium salicylate increased the amplitude of the insulin oscillations while the frequency remained stable. Sodium Salicylate 72-89 insulin Homo sapiens 15-22 6391745-3 1984 To challenge the hypothesis that prostaglandins may be instrumental in a generalized defect of glucose recognition in Type II diabetics, the effect of sodium salicylate on the hormonal counter-regulatory response to insulin-induced hypoglycaemia was examined. Sodium Salicylate 151-168 insulin Homo sapiens 216-223 6814899-3 1982 In the current study, we examined the effects of two known lipoxygenase inhibitors, BW755c and nordihydroguaiaretic acid, on the augmentation of insulin release evoked by three pharmacologically distinct classes of insulin secretagogues--one which augments cyclic AMP accumulation (exemplified by theophylline), one which inhibits prostaglandin synthesis (sodium salicylate), and one which is independent of changes in cyclic AMP or prostaglandin availability (tolbutamide). Sodium Salicylate 356-373 insulin Homo sapiens 145-152 7026970-3 1981 We examined the effects of infusions of either prostaglandin E2 (PGE2) or sodium salicylate (SS), a PG synthesis inhibitor, on the acute insulin responses (AIR"s) to arginine and isoproterenol and on the glucose potentiation of the insulin response to arginine in both normal and diabetic subjects. Sodium Salicylate 74-91 insulin Homo sapiens 137-144 7026970-3 1981 We examined the effects of infusions of either prostaglandin E2 (PGE2) or sodium salicylate (SS), a PG synthesis inhibitor, on the acute insulin responses (AIR"s) to arginine and isoproterenol and on the glucose potentiation of the insulin response to arginine in both normal and diabetic subjects. Sodium Salicylate 93-95 insulin Homo sapiens 137-144 7026970-7 1981 Similarly, SS augmented the AIR to an isoproterenol pulse in diabetics (SS = 38 +/- 9 microunits/ml, control = 18 +/- 3, n = 9, p less than .05) but not in normal subjects (SS = 19 +/- 4 microunits/ml, control = 21 +/- 4 microunits/ml, n = 8, p = ns), suggesting a SS-sensitive defect in the insulin response to these nonglucose stimuli in diabetics. Sodium Salicylate 11-13 insulin Homo sapiens 292-299 658622-0 1978 Restoration of the acute insulin response by sodium salicylate. Sodium Salicylate 45-62 insulin Homo sapiens 25-32 658622-2 1978 Adult-onset diabetics have markedly diminished or absent acute insulin responses to glucose that can be partially restored by sodium salicylate infusion. Sodium Salicylate 126-143 insulin Homo sapiens 63-70 4775868-0 1973 The effect of insulin on acute toxicity and transport of sodium salicylate into brain tissue. Sodium Salicylate 57-74 insulin Homo sapiens 14-21 330566-6 1977 Infusion of sodium salicylate (SS), an inhibitor of endogenous prostaglandin synthesis, augmented acute insulin responses to glucose in normals (response before SS = 313+/-62%; during SS = 660+/-86%; P < 0.001). Sodium Salicylate 12-29 insulin Homo sapiens 104-111 330566-6 1977 Infusion of sodium salicylate (SS), an inhibitor of endogenous prostaglandin synthesis, augmented acute insulin responses to glucose in normals (response before SS = 313+/-62%; during SS = 660+/-86%; P < 0.001). Sodium Salicylate 31-33 insulin Homo sapiens 104-111 5069697-0 1972 [Effect of insulin on sodium salicylate excretion from the body]. Sodium Salicylate 22-39 insulin Homo sapiens 11-18 19755670-9 2009 These data suggest that oral sodium salicylate at this dose impairs insulin clearance but does not ameliorate lipid-induced insulin resistance and beta-cell dysfunction in overweight and obese nondiabetic men. Sodium Salicylate 29-46 insulin Homo sapiens 68-75 5640773-0 1968 Effect of insulin on the transport and the analgesic action of sodium salicylates. Sodium Salicylate 63-81 insulin Homo sapiens 10-17 28740254-7 2017 In vivo, anti-IL-1beta, anti-TNFalpha or NF-kB inhibiting sodium salicylate treatment improved insulin secretion of isolated islets. Sodium Salicylate 58-75 insulin Homo sapiens 95-102 19755670-0 2009 The effect of high-dose sodium salicylate on chronically elevated plasma nonesterified fatty acid-induced insulin resistance and beta-cell dysfunction in overweight and obese nondiabetic men. Sodium Salicylate 24-41 insulin Homo sapiens 106-113 20617073-1 2010 Years before insulin was discovered, anti-inflammatory sodium salicylate was used to treat diabetes in 1901. Sodium Salicylate 55-72 insulin Homo sapiens 13-20